TY - JOUR
T1 - Molecular mechanisms in dizocilpine-induced attenuation of development of morphine dependence
T2 - An association with cortical Ca2+/calmodulin- dependent signal cascade
AU - Hamdy, Moustafa Mahmoud
AU - Noda, Yukihiro
AU - Miyazaki, Masayuki
AU - Mamiya, Takayoshi
AU - Nozaki, Ayumu
AU - Nitta, Atsumi
AU - Sayed, Merfat
AU - Assi, Abdel Azim
AU - Gomaa, Adel
AU - Nabeshima, Toshitaka
N1 - Funding Information:
This work was supported, in part, by Special Coordination Funds for Promoting Science and Technology, Target-oriented Brain Science Research Program, from the Ministry of Education, Culture, Sports, Science and Technology of Japan and by Health Science Research Grants for Research on Pharmaceutical and Medical Safety from the Ministry of Health, Labour and Welfare of Japan.
PY - 2004/7/9
Y1 - 2004/7/9
N2 - We investigated how dizocilpine, a non-competitive N-methyl-D-aspartate (NMDA) receptor antagonist, affects the development of morphine dependence in mice. Co-administration of dizocilpine (0.25 mg/kg) and morphine (10 mg/kg) for 5 days attenuated the development of tolerance to the antinociceptive effects of morphine. The withdrawal manifestation induced by the naloxone-challenge (5 mg/kg) was significantly reduced in mice that were treated with a combination of dizocilpine and morphine, compared to the mice treated with morphine and saline. The present study revealed a significant increase in c-Fos protein expression in the cortex and thalamus of mice showing naloxone-precipitated withdrawal syndrome. The combination of dizocilpine and morphine prevented the increase of c-Fos protein expression in the cortex and thalamus. Interestingly, repeated co-administration of dizocilpine and morphine prevented the withdrawal-induced phosphorylation of Ca2+/calmodulin kinase II (p-CaMK II) in the cortex, but not in the thalamus. Acute dizocilpine treatment prior to the naloxone-challenge and repeated treatment with dizocilpine alone had no effect on analgesia, withdrawal manifestations, p-CaMK II levels or c-Fos protein levels. These results showed that co-administration of dizocilpine and morphine prevented the development of morphine tolerance and dependence and suggested that the preventive effect of dizocilpine results from the regulation of c-Fos protein expression, which is possibly involved in the activation of the Ca2+/calmodulin-dependent signal cascade in the cortex.
AB - We investigated how dizocilpine, a non-competitive N-methyl-D-aspartate (NMDA) receptor antagonist, affects the development of morphine dependence in mice. Co-administration of dizocilpine (0.25 mg/kg) and morphine (10 mg/kg) for 5 days attenuated the development of tolerance to the antinociceptive effects of morphine. The withdrawal manifestation induced by the naloxone-challenge (5 mg/kg) was significantly reduced in mice that were treated with a combination of dizocilpine and morphine, compared to the mice treated with morphine and saline. The present study revealed a significant increase in c-Fos protein expression in the cortex and thalamus of mice showing naloxone-precipitated withdrawal syndrome. The combination of dizocilpine and morphine prevented the increase of c-Fos protein expression in the cortex and thalamus. Interestingly, repeated co-administration of dizocilpine and morphine prevented the withdrawal-induced phosphorylation of Ca2+/calmodulin kinase II (p-CaMK II) in the cortex, but not in the thalamus. Acute dizocilpine treatment prior to the naloxone-challenge and repeated treatment with dizocilpine alone had no effect on analgesia, withdrawal manifestations, p-CaMK II levels or c-Fos protein levels. These results showed that co-administration of dizocilpine and morphine prevented the development of morphine tolerance and dependence and suggested that the preventive effect of dizocilpine results from the regulation of c-Fos protein expression, which is possibly involved in the activation of the Ca2+/calmodulin-dependent signal cascade in the cortex.
UR - http://www.scopus.com/inward/record.url?scp=2942615473&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=2942615473&partnerID=8YFLogxK
U2 - 10.1016/j.bbr.2003.10.014
DO - 10.1016/j.bbr.2003.10.014
M3 - Article
C2 - 15196794
AN - SCOPUS:2942615473
SN - 0166-4328
VL - 152
SP - 263
EP - 270
JO - Behavioural Brain Research
JF - Behavioural Brain Research
IS - 2
ER -